Portfolio company
MyCural Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Myosin Therapeutics
This biopharmaceutical company develops small molecule therapies targeting molecular nanomotors to treat aggressive cancers and neurological disorders for patients with unmet medical needs.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
Accent Therapeutics
This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Chromacure
This company develops small molecule therapeutics for oncology patients to address unmet clinical needs in cancer treatment.
HYKU Biosciences
This biotechnology company develops precision covalent small-molecule medicines targeting disease-driving proteins to treat patients with cancer and other illnesses.
ARase Therapeutics
This company develops small molecule drugs targeting ADP-ribose hydrolases for patients with various forms of cancer.
Scorpion Therapeutics
This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.